Biologics·Jul 27, 2026
Amniotic products are format-driven — the same active biology behaves differently as a membrane, a micronized matrix, or a flowable suspension. These are the working protocols by clinical context.
Preparation and handling universals
- Verify Section 361 registration and lot documentation for every case.
- Cryopreserved: thaw per manufacturer instructions; single-use, no re-freeze.
- Dehydrated: reconstitute with sterile saline immediately before use.
- Documentation: photograph pre- and post-application; retain donor lot number.
Wound care protocols
Diabetic foot ulcer
- Sharp debridement to viable margins prior to allograft placement.
- Amniotic membrane sheet trimmed to wound size + 0.5 cm.
- Layer onto wound bed, secure with non-adherent dressing and off-loading device.
- Reapplication weekly for 4–8 weeks or until closure.
- Combine with standard offloading; without offloading, healing rates drop by 40%.
Venous stasis ulcer
- Compression bandaging is non-negotiable; amniotic is an adjunct, not a replacement.
- Weekly application ×4–6 weeks.
Chronic post-surgical wound
- Dehydrated micronized matrix reconstituted, applied to wound bed under a semi-occlusive dressing.
- Reapply every 3–7 days depending on exudate volume.
Aesthetic protocols
Post-procedure recovery (after CO₂, fractional, ablative work)
- Flowable matrix applied topically to freshly resurfaced skin within 4 hours.
- Reduces re-epithelialization time by 20–40% in published series.
- Follow with occlusive petrolatum for 24 hours.
Fractional dermal infusion facial rejuvenation
- Flowable matrix as infusion serum, alone or blended with HA.
- Series of 3–4 sessions at 4-week intervals.
Melasma and pigment protocols
- Micronized matrix + tranexamic acid, delivered via superficial microneedling.
- Series of 4 monthly sessions with photoprotection.
Post-microneedling application
- Flowable matrix applied topically after channel creation while channels are open.
- Alternative or complement to PRP for patients who prefer no blood draw.
Orthopedic protocols (evidence caveat)
Intra-articular amniotic injection remains a lower-evidence use than PRP or BMAC and should be discussed explicitly with patients. Some clinicians incorporate it as a bridge or adjunct; others reserve amniotic for wound care and aesthetics where the evidence base is stronger.
- Peri-tendinous soft tissue: 1–2 mL flowable matrix under ultrasound guidance.
- Combine with a graded loading program.
- Document indication rationale carefully.
Ocular surface protocols (specialist-led)
- Cryopreserved amniotic membrane placement for persistent epithelial defects.
- Requires ophthalmology training and specialized supplies.
Sequencing with devices
- Dermal infusion: flowable amniotic as the primary or blended serum; negative pressure improves matrix deposition at the DE junction.
- Microneedling: topical application post-needling into open channels.
- Fractional laser: apply flowable matrix within 4 hours of laser procedure for enhanced recovery.
- ECSWT: apply flowable to wound bed prior to shockwave over chronic wounds.
Head-to-head considerations
- vs PRP: amniotic offers higher growth factor concentration and matrix scaffolding but is allogeneic; PRP is autologous, lower-cost, and better characterized for MSK.
- vs exosome serum: amniotic provides matrix + growth factors; exosomes provide signaling vesicles. Complementary in many aesthetic protocols.
- vs synthetic biologics: amniotic's natural ECM composition is difficult to replicate synthetically; synthetics offer consistent dosing where allogeneic variability is unacceptable.
Common protocol failures
- Applying membrane to a poorly debrided wound bed — the tissue cannot integrate.
- Freezing dehydrated products — negates shelf stability.
- Under-dosing coverage — insufficient membrane area over the wound.
- Skipping documentation of donor lot — problematic for adverse event tracking.